Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 10107–10114 | Cite as

The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia

  • Jing Yang
  • Dong-ming Yao
  • Ji-chun Ma
  • Lei Yang
  • Hong Guo
  • Xiang-mei Wen
  • Gao-fei Xiao
  • Zhen Qian
  • Jiang Lin
  • Jun Qian
Original Article

Abstract

Recently, somatic mutations in SRSF2 gene have been discovered in a proportion of hematologic malignancies including acute myeloid leukemia (AML). This study was aimed to investigate SRSF2 mutations in Chinese AML patients. High-resolution melting analysis (HRMA) was developed to screen SRSF2 mutations in 249 cases with AML, and then direct DNA sequencing was used to verify the results of HRMA. In this study, 3.6 % (9/249) of Chinese AML patients were found with heterozygous SRSF2 mutations. Patients with SRSF2 mutations were older than those with wild-type SRSF2 (P = 0.014). No differences in the sex, blood parameters, French–American–British classification (FAB) subtypes, and karyotypes were observed between AML patients with and without SRSF2 mutations. Although the overall survival (OS) of SRSF2-mutated patients was inferior to those without mutations in both whole AML patients (median 4 vs. 11 months, respectively; P = 0.006) and cytogenetically normal patients (median 2 vs. 12 months, respectively; P = 0.008), multiple analysis disclosed that SRSF2 mutation was not an independent prognostic factor in AML patients. These results suggest that SRSF2 mutation occurs at a low frequency in aged AML patients and might not be associated with adverse prognosis in Chinese AML patients.

Keywords

SRSF2 mutation High-resolution melting analysis Acute myeloid leukemia Prognosis 

Notes

Acknowledgments

This study was supported by National Natural Science foundation of China (81172592, 81270630), Six major talent summit project in Jiangsu Province (WSN-112), Science and Technology Special Project in Clinical Medicine of Jiangsu Province (BL2012056), 333 Project of Jiangsu Province (BRA2013136), Science and Technology Infrastructure Program of Zhenjiang (SS2012003), Medical Key Talent Project of Zhenjiang, and Social Development Foundation of Zhenjiang (SH2013042, SH2014044, SH2014086).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29:475–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–66.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia. 2005;19:1361–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J. 2009;417:15–27.CrossRefPubMedGoogle Scholar
  10. 10.
    Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120:3080–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013;88:201–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119:3578–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120:4168–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012;119:3203–10.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012;120:3106–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119:4480–5.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.Google Scholar
  18. 18.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103:620–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Qian J, Lin J, Yao DM, Chen Q, Xiao GF, Ji RB, et al. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. Clin Chim Acta. 2010;411:2097–100.CrossRefPubMedGoogle Scholar
  20. 20.
    Yang J, Qian J, Yao DM, Qian SX, Qian W, Lin J, et al. SF3B1 mutation is a rare event in Chinese patients with acute and chronic myeloid leukemia. Clin Biochem. 2013;46:701–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Qian J, Yao DM, Lin J, Qian W, Wang CZ, Chai HY, et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One. 2012;7:e45760.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2012;91:519–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One. 2011;6:e26906.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Szankasi P, Jama M, Bahler DW. A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electropheresis. J Mol Diagn. 2008;10:236–41.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lin J, Yang J, Wen XM, Yang L, Deng ZQ, Qian Z, et al. Detection of SRSF2-P95 mutation by high-resolution melting curve analysis and its effect on prognosis in myelodysplastic syndrome. PLoS One. 2014;9:e115693.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, et al. Isolated trisomy 13 defines a genetically homogenous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124:1304–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H, Stephens J, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015;10:1239–45.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27:617–30.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of HematologyAffiliated People’s Hospital of Jiangsu UniversityZhenjiangChina
  2. 2.Department of Laboratory MedicineAffiliated People’s Hospital of Jiangsu UniversityZhenjiangChina
  3. 3.Laboratory CenterAffiliated People’s Hospital of Jiangsu UniversityZhenjiangChina

Personalised recommendations